Lord, Abbett & Co
BHVN

Lord, Abbett & Co’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Lord, Abbett & Co’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-317,429
Closed -$46.3M – 633
2022
Q2 		$46.3M Sell
317,429
-135,673
-30% -$17.3M 0.16% 179
2022
Q1 		$53.7M Buy
453,102
+174,775
+63% +$21.8M 0.14% 204
2021
Q4 		$38.4M Buy
278,327
+178,327
+178% +$22.7M 0.09% 305
2021
Q3 		$13.9M Buy
+100,000
New +$12.5M 0.03% 470

Other funds holding BHVN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SFM
Soros Fund Management New York $9.12B AUM 30.69% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Lord, Abbett & Co's BHVN Position: Q3 2022 in Review

Lord, Abbett & Co sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q3 2022, closing a stake of 317,429 shares — an estimated $46.3M sold.

Lord, Abbett & Co first reported a position in BHVN in Q3 2021 and held it in 4 quarters. The position peaked at $53.7M in Q1 2022. 240 funds tracked by Wall St. Rank hold BHVN as of Q3 2022.

  • Lord, Abbett & Co reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q3 2022 after selling out during the quarter.
  • Lord, Abbett & Co sold 317,429 Biohaven Pharmaceutical Holding Company Ltd. shares in Q3 2022, an estimated $46.3M.
  • Lord, Abbett & Co first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q3 2021 and held it in 4 quarters.
  • Lord, Abbett & Co's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $53.7M in Q1 2022.
  • 240 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q3 2022.

Based on Lord, Abbett & Co's 13F filing for Q3 2022, filed 14 Nov 2022.